Non-tumor-related prognostic factors for immunotherapy –chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)

AbstractBesides programmed death ligand 1 (PD-L1) expression, rapid, cost-effective and validated scores or models are critical for the prognosis and prediction of patients received immune checkpoint inhibitors (ICIs). In this retrospective study, 182 patients with NSCLC receiving ICIs from 2015 to 2022 were divided 1:1 into a training cohort and a validation cohort. We identified a score established by three factors and analyzed the prognostic implications by Kaplan –Meier approach (Log rank test) and time-dependent receiver operating characteristic (ROC) analyses. A non-tumor-related score (NTRS) was established that could be used as a prognostic factor (HR 2.260, 95% CI 1.559–3.276,P <  0.001 in training cohort; HR 2.114, 95% CI 1.493–2.994,P <  0.001 in validation cohort) and had a high time-dependent ROC for overall survival (OS) (AUC 0.670–0.782 in training cohort; AUC 0.682–0.841 in validation cohort). PD-L1 (1–49%) and NTRS (score = 0, 1, 2, 3) combination significantly improved the assessment of patients’ OS and progres s-free survival (PFS), which was statistically different in training cohorts (P <  0.001 for OS, 0.012 for PFS) and validation cohorts (P = 0.01 for OS, <  0.001 for PFS). The NTRS provided a better assessment of durable clinical benefit (DCB) compared to PD-L1 expression (P = 0.009 vs. 0.232 in training cohort;P = 0.004 vs. 0.434 in validation cohort). NTRS may help improve prognosis stratific...
Source: Clinical and Experimental Medicine - Category: Research Source Type: research